Patnaik, Amita
Gordon, Michael
Tsai, Frank
Papadopoulous, Kyri http://orcid.org/0000-0002-0667-2620
Rasco, Drew
Beeram, S. Muralidhar
Fu, Siqing
Janku, Filip http://orcid.org/0000-0002-8123-4065
Hynes, Scott M.
Gundala, Sushma R. http://orcid.org/0000-0001-6545-7763
Willard, Melinda D.
Zhang, Wei
Lin, Aimee Bence
Hong, David http://orcid.org/0000-0001-8721-1609
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 22 May 2018
Accepted: 12 June 2018
First Online: 20 June 2018
Change Date: 16 July 2018
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake. The co-authors’ names were incorrect.
Compliance with ethical standards
:
: AP has received institutional research funding from Eli Lilly. MG reports a pending patent on clinical trial decision-making. DR has served on a scientific advisory board for Eli Lilly. SF has received clinical study support from Aneropharma Science, Inc, Aprea AB, AstraZeneca, Eli Lilly, Endocyte, Ignyta, Millennium, NCCI, Novartis, OncoMed Pharmaceuticals, Inc, Vertex Pharmaceuticals, Inc, and Hengrui. FJ has received grant funding from Symphogen and Deciphera. SH, SRG, MDW, WZ, and ABL are employees and stockholders of Eli Lilly. ABL’s spouse is also an employee and stockholder of Eli Lilly. DH has received grant funding from Bayer, Eli Lilly, Genentech, LOXO, Pfizer, Amgen, Mirati, Ignyta, Merck, Daichii-Sanko, Eisai, and Mirno; travel fees from Mirna and LOXO; served as a consultant/advisor for Bayer, Baxter, and Guidepoint Global; and is the owner and founder of Oncoresponse. All other authors have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.